INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE

News provided by

Mar 25, 2024, 08:00 ET

SAN DIEGO, March 25, 2024 /PRNewswire/ -- DiCello Levitt LLP reminds investors that they have until the April 9, 2024 deadline to file their application for appointment as lead plaintiff in the shareholder class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX). This action is pending in the United States District Court for the Southern District of New York.

If you purchased shares of Amylyx securities between November 11, 2022 and November 8, 2023, and would like to discuss your legal rights and how this case might affect you and your right to recover your losses, you may, without obligation or cost to you, contact DiCello Levitt partner Brian O'Mara by calling (888) 287-9005 or at [email protected]. You may also learn more at https://dicellolevitt.com/securities/amylyx-pharmaceuticals/. If you wish to serve as a lead plaintiff in this class action, we can help you petition the Court by the April 9, 2024 deadline.

Case Allegations: The Amylyx lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) Amylyx had overstated RELYVRIO's commercial prospects; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) Amylyx had also overstated RELYVRIO's prescription rate; and (v) Amylyx hid the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data.

When the market learned the truth about the foregoing, Amylyx's stock price fell $5.74 per share, or 31.89%, to close at $12.26 per share on November 9, 2023.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

About DiCello Levitt:

At DiCello Levitt, we are dedicated to achieving justice for our clients through securities, class action, business-to-business, public client, whistleblower, personal injury, civil and human rights, and mass tort litigation. Our lawyers are highly respected for their ability to litigate and win cases—whether by trial, settlement, or otherwise—for people who have suffered harm, global corporations that have sustained significant economic losses, and public clients seeking to protect their citizens' rights and interests. Every day, we put our reputations—and our capital—on the line for our clients.

DiCello Levitt has achieved top recognition as 2023 Plaintiffs Firm of the Year and 2023 Trial Innovation Firm of the Year by the National Law Journal, in addition to its top-tier Chambers and Benchmark ratings. For more information about the Firm, including recent trial victories and case resolutions, please visit www.dicellolevitt.com.

Attorney Advertising. Prior results do not guarantee a similar outcome.

SOURCE DiCello Levitt LLP